According to Evoke Pharma, the United States Patent and Trademark Office (USPTO) has issued a notice of allowance for a patent that will protect the company’s Gimoti metaclopramide nasal spray until 2030. The patent (No. 11628150, “Nasal Formulation of Metoclopramide”) is expected to be issued on April 18, 2023. Other patents covering Gimoti include Nos. 11,020,361 and 8,334,281, both titled “Nasal Formulations of Metoclopramide,” and No. 11,517,545, titled, “Treatment of Moderate and Severe Gastroparesis,” issued in December 2022.
Gimoti was approved by the FDA for the treatment of diabetic gastroparesis in June 2020 and in April 2022, the company was granted 3 years of market exclusivity for the nasal spray.
Evoke Pharma President and Chief Operating Officer Matt D’Onofrio commented, “The novelty of Gimoti is crucial for the work we do every day to ensure better outcomes for gastroparesis patients. We continue to develop and grow the product in the market and are pleased to fortify our patent estate once again. Aside from the clinical benefit our product provides to patients and healthcare providers, we believe the addition of this new patent signifies the value and contribution of Gimoti to the field of GI motility.”
Read the Evoke Pharma press release.
